title: Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model.
abstract: BACKGROUND
  Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compounds, such as palmitoylethanolamine, the role of CBR agonists on inflammatory skin diseases is not yet fully understood. This study was performed to investigate the effects of CBR agonists on skin inflammation, using acute and chronic inflammation animal models.
  
  
  METHODS
  The effectiveness of the newly synthesized cannabinoid receptor 1 (CB1R) agonists was determined using in vitro assays. Markers for epidermal permeability barrier function and skin inflammation were measured, and histological assessments were performed for evaluation.
  
  
  RESULTS
  Topical application of CB1R-specific agonist significantly accelerated the recovery of epidermal permeability barrier function and showed anti-inflammatory activity in both acute and chronic inflammation models. Histological assessments also confirmed the anti-inflammatory effects, which is consistent with previous reports.
  
  
  CONCLUSIONS
  All of the results suggest that topical application of CB1R-specific agonist can be beneficial for alleviating the inflammatory symptoms in chronic skin diseases, including atopic dermatitis.
authors.affiliation: Department of Dermatology, Atopy Clinic, Seoul Medical Center, Seoul, Korea.
authors.forename: Hyun Jong
authors.initials: HJ
authors.lastname: Kim
authors.affiliation: CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
authors.forename: Bongwoo
authors.initials: B
authors.lastname: Kim
authors.affiliation: CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
authors.forename: Bu Man
authors.initials: BM
authors.lastname: Park
authors.affiliation: CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
authors.forename: Jeong Eun
authors.initials: JE
authors.lastname: Jeon
authors.affiliation: CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.
authors.forename: Sin Hee
authors.initials: SH
authors.lastname: Lee
authors.affiliation: College of Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
authors.forename: Shivtaj
authors.initials: S
authors.lastname: Mann
authors.affiliation: Department of Dermatology, Wonju College of Medicine, Yonsei University, Kangwon, Korea.
authors.forename: Sung Ku
authors.initials: SK
authors.lastname: Ahn
authors.affiliation: Department of Dermatology, College of Medicine, Dankook University, Chungnam, Korea.
authors.forename: Seung-Phil
authors.initials: SP
authors.lastname: Hong
authors.affiliation: CRID Center, NeoPharm Co., Ltd., Daejeon, Korea.|Department of Pharmaceutics, College of Pharmacy, Chungbook National University, Chungbook, Korea.
authors.forename: Se Kyoo
authors.initials: SK
authors.lastname: Jeong
mesh_terms: D000208:Acute Disease; D000279:Administration, Cutaneous; D000818:Animals; D063386:Cannabinoid Receptor Agonists / Q000494:pharmacology*; D002908:Chronic Disease; D003876:Dermatitis, Atopic / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology*; D005260:Female; D008807:Mice, Inbred BALB C; D010081:Oxazolone; D010539:Permeability / Q000187:drug effects; D011412:Propanolamines / Q000494:pharmacology*; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists; D012867:Skin / Q000378:metabolism*; D012879:Skin Physiological Phenomena / Q000187:drug effects*; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives; D014870:Water Loss, Insensible
chemical_list: C554292:12-O-tetradecanoylphorbol-1,3-acetate; D063386:Cannabinoid Receptor Agonists; D005231:Fatty Acids, Unsaturated; D011412:Propanolamines; D043884:Receptor, Cannabinoid, CB1; C000608600:alpha-oleoyl oleylamine serinol; D010081:Oxazolone; D013755:Tetradecanoylphorbol Acetate